» Articles » PMID: 35662448

Anaplastic Thyroid Cancer: New Horizons and Challenges

Overview
Publisher Elsevier
Specialty Endocrinology
Date 2022 Jun 6
PMID 35662448
Authors
Affiliations
Soon will be listed here.
Abstract

Anaplastic thyroid cancer (ATC) remains one of the most aggressive and deadliest malignancies. Traditionally, treatment consisted of cytotoxic chemotherapy and radiation therapy, with or without surgery, although a large proportion of patients were often directed toward palliative/hospice care. In the past decade, significant advances have been made through the advent of targeted therapies and immunotherapy. For patients with targetable disease and considerable treatment response, surgery and other multidisciplinary adjuvant therapies can now be considered. Overall, the era of untreatable ATC is progressively being replaced by highly personalized multidisciplinary therapies, actively shifting the treatment pendulum of this disease.

Citing Articles

Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.

Valerio L, Matrone A Explor Target Antitumor Ther. 2025; 6:1002291.

PMID: 40061140 PMC: 11886382. DOI: 10.37349/etat.2025.1002291.


Celastrol promotes apoptotic cell death in thyroid cancer cells through a caspases-dependent pathway.

Yang R, Yao J, Ma H, Shui C, Li T, Zhang S Thyroid Res. 2025; 18(1):9.

PMID: 40001245 PMC: 11863774. DOI: 10.1186/s13044-024-00222-7.


Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer.

Benson P, Abdel-Rahman O Immunotherapy. 2025; 17(1):47-55.

PMID: 39895320 PMC: 11834419. DOI: 10.1080/1750743X.2025.2455922.


Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report.

Fan S, Yuan Y, Su Y, Sang D SAGE Open Med Case Rep. 2025; 13:2050313X241313084.

PMID: 39877673 PMC: 11773542. DOI: 10.1177/2050313X241313084.


New Horizons of Biomarkers in Metastatic Thyroid Cancer.

Cendra A, Pekarek L, Pedrejon B, Bernier L, Cervantes E, Cendra C J Cancer. 2025; 16(1):241-264.

PMID: 39744583 PMC: 11660124. DOI: 10.7150/jca.101395.